Hypofractionated Radiotherapy plus Cetuximab in Locally Advanced Head and Neck Cancer

Teoh, Daren; Rodger, S.; Say, J.; Hartley, A.

doi:10.1016/j.clon.2008.07.003

Cited by 8 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This regime employs a fraction size of 2.6 Gy per fraction. The 4-week regime 55 Gy in 20# over 25 days has historically been used with several single agents including methotrexate, cetuximab, carboplatin and capecitabine for locally advanced diseases [13][14][15][16][17][18]. More recent IMRT series have used 55 Gy in 20 fractions with synchronous single agent cisplatin, carboplatin and cetuximab [8,19,20].…”

Section: Discussionmentioning

confidence: 99%

A Phase II Trial of Moderate Hypofractionated Chemoradiation In Postoperative Cases of Carcinoma Oral Cavity

Raza

2023

CTOIJ

View full text Add to dashboard Cite

Introduction: Conventional fractionation in post-operative adjuvant radiotherapy (usually 60 Gy in 2 Gy per fraction delivered over six weeks) remains the standard in carcinoma oral cavity. Post-operative hypofractionated radiotherapy is less explored especially in post-operative oral cavity cancers. The aim of this study is to evaluate postoperative moderate hypofractionation as the adjuvant treatment in post-operative oral cavity cancer.Method: Patients of oral cavity cancers meriting adjuvant postoperative irradiation were inducted in the study. Hypofractionation consisted of a total dose of 52 Gy in 20 fractions over 4 weeks with concurrent chemotherapy. The primary endpoint was acute toxicity and late toxicity according to CTCAE V4.03 classification. The secondary endpoints included progression free survival at 1 year. Acute toxicity within 3 months of treatment and late toxicity at 1year follow up.Result: Thirty patients were recruited over 18 months. All patients completed a minimum of 1 year of follow-up. Twenty-Nine patients completed planned radiotherapy doses within a median treatment time of 30 days (27)(28)(29)(30)(31)(32)(33). Grade 2, 3and 4 skin reactions were seen in 86.2%, 10.34%, and 3.4% respectively. Grade 2,3,4 mucositis was seen in 55.17%, 41.3%, 3.4% patients respectively during treatment (acute toxicity). Recurrence was seen in 17% of patients at 3 months. Progression free survival at 1 year was 51%. Overall survival in 1 year was 79%. Conclusion:The schedule of 52 Gy in 20 fractions with concomitant chemotherapy is tolerable in patients with better compliance and equivalent PFS to conventional fractionation postoperative radiotherapy. Phase 3 trial is required for further validation of results.

show abstract

Section: Discussionmentioning

confidence: 99%

A Phase II Trial of Moderate Hypofractionated Chemoradiation In Postoperative Cases of Carcinoma Oral Cavity

Raza

2023

CTOIJ

View full text Add to dashboard Cite

show abstract

“…The 4 week regime 55 Gy in 20# over 25 days has historically been used with several single agents including methotrexate, cetuximab, carboplatin and capecitabine for locally advanced disease disease [28] , [29] , [30] , [31] , [32] , [33] . More recent IMRT series have used 55 Gy in 20 fractions with synchronous single agent cisplatin, carboplatin and cetuximab [13] , [34] , [35] .…”

Section: Discussionmentioning

confidence: 99%

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

et al. 2021

View full text Add to dashboard Cite

“…Several reasons could explain discrepancies in incidence rates; these can include the use of different toxicity classification systems, bias in the selection of patients, and the use of different techniques and radiation doses. Additionally, observational data suggest that, natural killer although there could be a greater incidence of grade 3 or 4 radiodermatitis in patients with BRT compared with chemoradiotherapy (CRT), CRT adverse effects could exert a greater negative impact on symptomatology severity and therapy compliance …”

Section: Bioradiodermatitismentioning

confidence: 99%

Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck

Villavicencio¹,

Granados-García²,

Vilajosana

et al. 2017

Int J Dermatology

View full text Add to dashboard Cite

The objective of this review is to report to the medical community the most recent knowledge on prevention and management of dermatitis with the use of cetuximab simultaneously with radiotherapy in the treatment of squamous cell carcinomas of the head and neck. A review was conducted in PubMed of English language publications between 2010 and 2015. The search employed the terms 'skin toxicity', 'radiodermatitis', 'cetuximab', 'radiotherapy', and 'head and neck cancer'. Data related to the classification and management of dermatitis, associated with cetuximab with concomitant radiotherapy (n = 22), were critically reviewed. We conclude that dermatitis associated with bioradiotherapy is a predictable, treatable, and reversible event that does not affect administration of therapy or its clinical outcome when treated appropriately.

show abstract

Hypofractionated Radiotherapy plus Cetuximab in Locally Advanced Head and Neck Cancer

Cited by 8 publications

References 4 publications

A Phase II Trial of Moderate Hypofractionated Chemoradiation In Postoperative Cases of Carcinoma Oral Cavity

A Phase II Trial of Moderate Hypofractionated Chemoradiation In Postoperative Cases of Carcinoma Oral Cavity

Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial

Management of radiodermatitis associated with cetuximab in squamous cell carcinomas of the head and neck

Contact Info

Product

Resources

About